Meeting
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
Authors
Jeffrey Thomas Yorio
Texas Oncology PA, Austin, TX
Jeffrey Thomas Yorio , Aviva G. Asnis-Alibozek , Vijay Kasturi , Thomas E. Hutson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 629)
DOI
10.1200/JCO.2023.41.6_suppl.629
Abstract #
629
Poster Bd #
E19
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity from first-line TKI plus IO therapies for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
First Author: Neil J. Shah